MX2015008847A - Composiciones inmunogenicas de virus de influenza y usos de las mismas. - Google Patents

Composiciones inmunogenicas de virus de influenza y usos de las mismas.

Info

Publication number
MX2015008847A
MX2015008847A MX2015008847A MX2015008847A MX2015008847A MX 2015008847 A MX2015008847 A MX 2015008847A MX 2015008847 A MX2015008847 A MX 2015008847A MX 2015008847 A MX2015008847 A MX 2015008847A MX 2015008847 A MX2015008847 A MX 2015008847A
Authority
MX
Mexico
Prior art keywords
influenza virus
rna
epitope
immunogenic compositions
component
Prior art date
Application number
MX2015008847A
Other languages
English (en)
Inventor
Andrew Geall
Sylvie Carine Bertholet Girardin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2015008847A publication Critical patent/MX2015008847A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

Se describen composiciones inmunogénicas que comprenden un componente de ARN y un componente de polipéptido. El componente de ARN es un ARN auto-replicante. El componente de polipéptido comprende un epítopo de un antígeno del virus de influenza (el primer epítopo), y el componente de ARN codifica un polipéptido que también comprende un epítopo de un antígeno del virus de influenza (el segundo epítopo). El suministro de epítopos en estas dos maneras diferentes puede mejorar la respuesta inmunitaria al virus de la gripe en comparación con la inmunización con el ARN o el polipéptido solo.
MX2015008847A 2013-01-10 2014-01-10 Composiciones inmunogenicas de virus de influenza y usos de las mismas. MX2015008847A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361751077P 2013-01-10 2013-01-10
PCT/EP2014/050414 WO2014108515A1 (en) 2013-01-10 2014-01-10 Influenza virus immunogenic compositions and uses thereof

Publications (1)

Publication Number Publication Date
MX2015008847A true MX2015008847A (es) 2015-10-30

Family

ID=49956176

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008847A MX2015008847A (es) 2013-01-10 2014-01-10 Composiciones inmunogenicas de virus de influenza y usos de las mismas.

Country Status (10)

Country Link
US (1) US20140193484A1 (es)
EP (1) EP2943221A1 (es)
JP (2) JP2016506416A (es)
CN (2) CN109045294A (es)
AU (2) AU2014204826A1 (es)
CA (1) CA2897752A1 (es)
HK (1) HK1214962A1 (es)
MX (1) MX2015008847A (es)
RU (1) RU2015132962A (es)
WO (1) WO2014108515A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011123495A1 (en) 2010-03-30 2011-10-06 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
SI2591114T1 (sl) 2010-07-06 2016-10-28 Glaxosmithkline Biologicals S.A. Imunizacija velikih sesalcev z majhnimi odmerki RNA
HUE026646T2 (en) 2010-07-06 2016-07-28 Glaxosmithkline Biologicals Sa Preferred liposomes containing lipids of PKA value for delivery of RNA
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
HUE060524T2 (hu) 2010-08-31 2023-03-28 Glaxosmithkline Biologicals Sa Pegilált liposzómák immunogén kódoló RNS beszállítására
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
EP3520813B1 (en) 2010-10-11 2023-04-19 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
EP3854413A1 (en) * 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US10131695B2 (en) 2011-09-20 2018-11-20 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
LT2791160T (lt) 2011-12-16 2022-06-10 Modernatx, Inc. Modifikuotos mrnr sudėtys
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2014028429A2 (en) 2012-08-14 2014-02-20 Moderna Therapeutics, Inc. Enzymes and polymerases for the synthesis of rna
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
KR20150104117A (ko) 2012-12-18 2015-09-14 이칸 스쿨 오브 메디슨 엣 마운트 시나이 인플루엔자 바이러스 백신 및 그의 용도
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CN106659803A (zh) 2014-04-23 2017-05-10 摩登纳特斯有限公司 核酸疫苗
AU2016209032A1 (en) 2015-01-23 2017-08-10 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
CA2975816A1 (en) 2015-05-15 2016-11-24 Curevac Ag Prime-boost regimens involving administration of at least one mrna construct
US10849920B2 (en) 2015-10-05 2020-12-01 Modernatx, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
WO2017070620A2 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Broad spectrum influenza virus vaccine
CN108778365B (zh) 2016-01-11 2021-05-25 沃达瑞公司 微针组合物及其使用方法
CN105664149A (zh) * 2016-02-24 2016-06-15 华东理工大学 一种多抗原流感通用疫苗及其制备方法
JP7237344B2 (ja) 2016-06-15 2023-03-13 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルス血球凝集素タンパク質及びその使用
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
US11141377B2 (en) * 2017-06-15 2021-10-12 Infectious Disease Research Institute Nanostructured lipid carriers and stable emulsions and uses thereof
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
JP7355731B2 (ja) 2017-08-16 2023-10-03 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子製剤における使用のための脂質
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
JP2021534182A (ja) * 2018-08-17 2021-12-09 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物及びその使用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
CA2204254C (en) 1994-11-17 2010-02-16 Stephen Lewis Hart Internalisation of dna, using conjugates of poly-l-lysine and an integrin receptor ligand
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6090619A (en) 1997-09-08 2000-07-18 University Of Florida Materials and methods for intracellular delivery of biologically active molecules
HUP0202846A3 (en) 1999-09-24 2003-12-29 Smithkline Beecham Biolog Intranasal influenza virus vaccine
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
JP2004536785A (ja) 2001-02-23 2004-12-09 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規なワクチン
DK1361890T3 (da) 2001-02-23 2011-06-27 Glaxosmithkline Biolog Sa Influenzavaccineformuleringer til intradermal indgift
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
ES2618309T3 (es) * 2002-12-13 2017-06-21 Alphavax, Inc. Partículas de replicón de alfavirus multi-antigénico y métodos
ATE471335T1 (de) 2002-12-23 2010-07-15 Vical Inc Impfstoffe gegen infektionen mit dem humanen zytomegalivirus auf grundlage von codonoptimierten polynukleotiden
CN1791678A (zh) * 2003-03-20 2006-06-21 阿尔法瓦克斯公司 改进的甲病毒复制子和辅助构建体
EP2581093B1 (en) * 2003-06-16 2015-03-18 MedImmune, LLC Influenza hemagglutinin and neuraminidase variants
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
WO2005116270A2 (en) 2004-05-18 2005-12-08 Vical Incorporated Influenza virus vaccine composition and method of use
ATE420965T1 (de) 2004-05-18 2009-01-15 Alphavax Inc Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren
ATE536418T1 (de) 2004-06-07 2011-12-15 Protiva Biotherapeutics Inc Lipidverkapselte interferenz-rna
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
EP2037959B1 (en) * 2006-06-07 2016-01-27 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
EP2069376A4 (en) * 2006-07-21 2013-10-16 Pharmexa Inc INDUCTION OF CELLULAR IMMUNE RESPONSES TO INFLUENZA VIRUS BY COMPOSITIONS OF PEPTIDES AND NUCLEIC ACIDS
NZ575901A (en) * 2006-09-12 2012-04-27 Alphavax Inc Alphavirus replicon particles matched to protein antigens as immunological adjuvants
US20110045022A1 (en) 2006-12-06 2011-02-24 Theodore Tsai Vaccines including antigen from four strains of influenza virus
JP2010519203A (ja) * 2007-02-16 2010-06-03 メルク・シャープ・エンド・ドーム・コーポレイション 生物活性分子の活性を強化するための組成物及び方法
EA017887B1 (ru) * 2007-08-02 2013-03-29 Байондвакс Фармасьютикалз Лтд. Полимерные мультиэпитопные вакцины против гриппа
WO2009132206A1 (en) 2008-04-25 2009-10-29 Liquidia Technologies, Inc. Compositions and methods for intracellular delivery and release of cargo
CN102149405A (zh) * 2008-07-11 2011-08-10 米迪缪尼股份有限公司 流感血凝素和神经氨酸酶变体
EP2328614A1 (en) * 2008-08-06 2011-06-08 Novartis AG Microparticles for use in immunogenic compositions
US20110300205A1 (en) * 2009-07-06 2011-12-08 Novartis Ag Self replicating rna molecules and uses thereof
HRP20220756T1 (hr) * 2009-07-15 2022-09-02 Glaxosmithkline Biologicals S.A. Proteinski pripravci rsv f i postupci za izradu istih
JP5988492B2 (ja) * 2009-09-02 2016-09-07 ノバルティス アーゲー Ｔｌｒ活性モジュレーターを含む免疫原性組成物
TWI445708B (zh) * 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
WO2011056802A1 (en) * 2009-11-03 2011-05-12 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Influenza virus recombinant proteins
EP2525815B1 (en) * 2010-01-24 2015-02-25 Novartis AG Irradiated biodegradable polymer microparticles
SI2591114T1 (sl) * 2010-07-06 2016-10-28 Glaxosmithkline Biologicals S.A. Imunizacija velikih sesalcev z majhnimi odmerki RNA
MX343410B (es) * 2010-07-06 2016-11-04 Novartis Ag * Emulsiones cationicas de agua en aceite.
CN103154242B (zh) * 2010-07-06 2015-09-30 诺华股份有限公司 诺如病毒衍生的免疫原性组合物和方法
HUE026646T2 (en) 2010-07-06 2016-07-28 Glaxosmithkline Biologicals Sa Preferred liposomes containing lipids of PKA value for delivery of RNA
SI2590676T1 (sl) * 2010-07-06 2016-11-30 Glaxosmithkline Biologicals, S.A. Virionu podobni delci za dajanje za samorepliciranje RNA molekul
US9192661B2 (en) * 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
US9770463B2 (en) * 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
HUE047796T2 (hu) * 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
AU2011295938B2 (en) 2010-08-31 2016-01-14 Glaxosmithkline Biologicals S.A. Lipids suitable for liposomal delivery of protein-coding RNA
HUE060524T2 (hu) * 2010-08-31 2023-03-28 Glaxosmithkline Biologicals Sa Pegilált liposzómák immunogén kódoló RNS beszállítására
SI4008357T1 (sl) 2010-08-31 2023-04-28 Glaxosmithkline Biologicals Sa Mali liposomi za dostavo imunogen-kodirajoče RNA
EP2614072A4 (en) * 2010-09-09 2014-03-19 Univ Virginia Commonwealth VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
EP3520813B1 (en) * 2010-10-11 2023-04-19 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
EP2667892B1 (en) * 2011-01-26 2019-03-27 GlaxoSmithKline Biologicals SA Rsv immunization regimen
SG194755A1 (en) * 2011-05-13 2013-12-30 Novartis Ag Pre-fusion rsv f antigens
RU2014104090A (ru) * 2011-07-06 2015-08-20 Новартис Аг Липосомы с эффективным соотношением n:p для доставки молекул phk
AU2012280901B2 (en) * 2011-07-06 2016-11-10 Glaxosmithkline Biologicals S.A. Oil-in-water emulsions that contain nucleic acids
EP3854413A1 (en) * 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
BR112014000235A8 (pt) 2011-07-06 2018-03-06 Novartis Ag emulsões de óleo em água catiônicas
JP2014520807A (ja) 2011-07-06 2014-08-25 ノバルティス アーゲー 免疫原性組成物およびその使用
CA2846043A1 (en) * 2011-08-31 2013-03-07 Novartis Ag Pegylated liposomes for delivery of immunogen-encoding rna
CA2872033A1 (en) * 2011-10-11 2013-04-18 Novartis Ag Recombinant self-replicating polycistronic rna molecules
US20140348863A1 (en) * 2011-10-12 2014-11-27 Alessia Bianchi Cmv antigens and uses thereof
US9504747B2 (en) * 2013-03-08 2016-11-29 Novartis Ag Lipids and lipid compositions for the delivery of active agents

Also Published As

Publication number Publication date
RU2015132962A (ru) 2017-02-14
AU2018260983A1 (en) 2018-12-06
EP2943221A1 (en) 2015-11-18
CN104902925A (zh) 2015-09-09
CN109045294A (zh) 2018-12-21
US20140193484A1 (en) 2014-07-10
JP2016506416A (ja) 2016-03-03
CA2897752A1 (en) 2014-07-17
WO2014108515A1 (en) 2014-07-17
JP2018035195A (ja) 2018-03-08
HK1214962A1 (zh) 2016-08-12
AU2014204826A1 (en) 2015-07-09

Similar Documents

Publication Publication Date Title
MX2015008847A (es) Composiciones inmunogenicas de virus de influenza y usos de las mismas.
PH12017500727A1 (en) Modified virus-like particles of cmv
WO2013006842A3 (en) Self-replicating rna prime - protein boost vaccines
MX2018009990A (es) Metodos para mejorar la eficacia de una vacuna mediante la administracion de un antagonista il-4r.
WO2013054199A3 (en) Cmv antigens and uses thereof
WO2011103453A3 (en) Vaccines for use in the prophylaxis and treatment of influenza virus disease
MX2016010954A (es) Construcciones de proteina superficial ubicua a2 y usos de las mismas.
NZ729519A (en) Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
MX340796B (es) Composiciones y procedimientos antigenicos del virus respiratorio sincitial.
WO2014150822A3 (en) Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
PH12015501716A1 (en) Anti-mycoplasma spp. subunit vaccine
MX2014011712A (es) Composiciones antigenas y procedimientos.
WO2014160747A3 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
EA201691638A1 (ru) Новые способы индуцирования иммунного ответа
PH12014501795A1 (en) Rota virus subunit vaccines and methods of making and use thereof
MX2019007252A (es) Metodos y composiciones para vacunas del virus del dengue.
EA201792512A1 (ru) Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник
IN2014DN09445A (es)
MX2019007924A (es) Vacunas contra la influenza.
EA201690378A1 (ru) Вакцинные композиции против наркотической зависимости
MX2016009952A (es) Proteinas y antigenos del virus de diarrea epidemica porcino (pedv).
MX2017014146A (es) Glicoproteína de hemaglutinina h7 modificada de la secuencia de influenza a/shanghai/2/2013 h7.
WO2015070207A3 (en) Ama-1 epitopes, antibodies, compositions, and methods of making and using the same